secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127107
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 3.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics completes merger with Peak Bio, secures $3.2M PIPE and $50M ELOC term sheet
--------------------------------------------------------------------------------

- Merger closed; Peak Bio shareholders received 0.2935 Akari ADS per share, representing ~48.4% of combined entity on fully diluted basis.
- Private placement of 1,713,402 ADSs+Warrants at $1.70/unit ($2.385 for insiders) for aggregate gross proceeds of $3.2M.
- Entered term sheet for up to $50M equity line of credit with White Lion Capital over 3 years, subject to registration statement.
- Nasdaq delisting risk resolved; company believes it now meets $2.5M stockholders' equity requirement post-merger.
- Board changes: Wa'el Hashad and Donald Williams resigned; Hoyoung Huh (non-executive chairman), James Neal, Sandip Patel appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/aktx-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer